Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience
- 28 December 2013
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 8 (1) , 137-145
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled TrialAmerican Journal of Transplantation, 2012
- A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation—PROTECTAmerican Journal of Transplantation, 2012
- Sirolimus-Based Immunosuppression in Liver Transplantation for Hepatocellular CarcinomaLiver Transplantation, 2012
- Timing of Conversion to Mammalian Target of Rapamycin Inhibitors Is Crucial in Liver Transplant Recipients With Impaired Renal Function at TransplantationTransplantation Proceedings, 2010
- Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal FunctionAmerican Journal of Transplantation, 2010
- Effect of Different Immunosuppressive Schedules on Recurrence-Free Survival After Liver Transplantation for Hepatocellular CarcinomaTransplantation, 2010
- Conceptual Model of CKD: Applications and ImplicationsAmerican Journal of Kidney Diseases, 2009
- Long‐term renal function after liver transplantation is related to calcineurin inhibitors blood levelsClinical Transplantation, 2005
- Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimusLiver Transplantation, 2003
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999